GENE EDITING 101
All Companies
🇨🇳

EdiGene / Correcta Therapeutics

Private

China's CRISPR and RNA editing leader

EdiGene is a clinical-stage biotechnology company using CRISPR and its proprietary LEAPER RNA editing platform to develop therapies for genetic disorders, cancer, and chronic diseases. It was one of the first Chinese companies to take CRISPR therapies into clinical trials.

Founded2015
HQBeijing, China
CEODong Wei
StatusPrivate
Total Funding$300M

Pipeline

Drug / ProgramIndicationPhaseTechnology
ET-01Beta-ThalassemiaPhase 1CRISPR-Cas9
LEAPER programsGenetic disordersPreclinicalRNA Editing

Key People

Dong WeiCEO & Founder

Related Articles

CRISPR Companies to Watch in 2026: Who's Leading the Gene Editing Revolution?
Biotech Companies
Market Analysis

CRISPR Companies to Watch in 2026: Who's Leading the Gene Editing Revolution?

A comprehensive look at the CRISPR companies shaping the future of medicine in 2026, from approved therapies to next-generation editing platforms.

Mar 16, 20266 min read